Trajectory of blood pressure after initiating anti-calcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration
ConclusionsOur findings suggest that anti-CGRP treatment is safe regarding blood pressure in patients without hypertension. However, for those with baseline hypertension, anti-CGRP treatment resulted in a small but persistent increase in the number of antihypertensives, indicating an exacerbation of hypertension. Future studies are needed to evaluate the cardio-cerebrovascular safety of anti-CGRP treatment beyond the first four years.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research
More News: Cardiology | Chronic Pain | Clinical Trials | Genetics | Headache | Heart | Hypertension | Migraine | Neurology | Pain | Study | Topamax | Women